The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Open accessAbstract
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to improve with the incorporation of this new class of agents with current MM therapies. However, both antigens are also expressed on other normal tissues including hematopoietic lineages and immune effector cells, which may limit their long-term clinical use. B cell maturation antigen (BCMA), a transmembrane glycoprotein in the tumor necrosis factor receptor superfamily 17 (TNFRSF17), is expressed at significantly higher levels in all patient MM cells but not on other normal tissues except normal plasma cells. Importantly, it is an antigen targeted by chimeric antigen receptor (CAR) T-cells, which have already shown significant clinical activities in patients with RRMM who have undergone at least three prior treatments, including a proteasome inhibitor and an immunomodulatory agent. Moreover, the first anti-BCMA antibody-drug conjugate also has achieved significant clinical responses in patients who failed at least three prior lines of therapy, including an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulatory agent. Both BCMA targeting immunotherapies were granted breakthrough status for patients with RRMM by FDA in Nov 2017. Other promising BCMA-based immunotherapeutic macromolecules including bispecific T-cell engagers, bispecific molecules, bispecific or trispecific antibodies, as well as improved forms of next generation CAR T cells, also demonstrate high anti-MM activity in preclinical and even early clinical studies. Here, we focus on the biology of this promising MM target antigen and then highlight preclinical and clinical data of current BCMA-targeted immunotherapies with various mechanisms of action. These crucial studies will enhance selective anti-MM response, transform the treatment paradigm, and extend disease-free survival in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Self-citationReview of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationStrategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationAdoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W., Parrish-Novak, J., Foster, D., Lofton-Day, C., et al. (2000) · Nature · doi:10.1038/35010115 · Cited by 1,174
BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells
O'Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K., Ahonen, C., Lin, L.-L., Mantchev, G. T., Bram, R. J., & Noelle, R. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031330 · Cited by 1,128
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
BAFF and APRIL: A Tutorial on B Cell Survival
Mackay, F., Schneider, P., Rennert, P., & Browning, J. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141152 · Cited by 1,007
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Self-citationThe genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913 · cited 1×
“Clin Lymphoma Myeloma Leuk (2016) 16(10):537–42.”
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 757
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
IRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
Site-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 653
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C., & Chen, Y. Y. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0231 · Cited by 607
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592 · cited 1×
“This unique structure allows BiTE to engage T-cells with tumor cells (111).”
BackgroundGenomic complexity of multiple myeloma and its clinical implications
Manier, S., Salem, K. Z., Park, J., Landau, D. A., Getz, G., & Ghobrial, I. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.122 · Cited by 560
Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Ruella, M., Barrett, D. M., Kenderian, S. S., Shestova, O., Hofmann, T. J., Perazzelli, J., Klichinsky, M., Aikawa, V., Nazimuddin, F., Kozlowski, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87366 · Cited by 558
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
Novak, A. J., Darce, J. R., Arendt, B. K., Harder, B., Henderson, K., Kindsvogel, W., Gross, J. A., Greipp, P. R., & Jelinek, D. F. (2004) · Blood · doi:10.1182/blood-2003-06-2043 · Cited by 554
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells
Avery, D. T., Kalled, S. L., Ellyard, J. I., Ambrose, C., Bixler, S. A., Thien, M., Brink, R., Mackay, F., Hodgkin, P. D., & Tangye, S. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18025 · Cited by 509
Rosiñol, L., Oriol, A., Teruel, A. I., Hernández, D., López-Jiménez, J., de la Rubia, J., Granell, M., Besalduch, J., Palomera, L., González, Y., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408922 · Cited by 486
Tai, Y.-T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J., Yates, J., Gliddon, L., Fieles, W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 484
Self-citationCutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL
Benson, M. J., Dillon, S. R., Castigli, E., Geha, R. S., Xu, S., Lam, K.-P., & Noelle, R. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3655 · Cited by 478
Klinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R. C., Topp, M. S., Gökbuget, N., Neumann, S., Goebeler, M., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-400515 · Cited by 471
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Thompson, J. S., Schneider, P., Kalled, S. L., Wang, L., Lefevre, E. A., Cachero, T. G., MacKay, F., Bixler, S. A., Zafari, M., Liu, Z.-Y., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.129 · Cited by 394
Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
McCombs, J. R., & Owen, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9710-8 · Cited by 393
Görgün, G. T., Whitehill, G., Anderson, J. L., Hideshima, T., Maguire, C., Laubach, J., Raje, N., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2013) · Blood · doi:10.1182/blood-2012-08-448548 · Cited by 393
Self-citationTargeting the bone marrow microenvironment in multiple myeloma
Kawano, Y., Moschetta, M., Manier, S., Glavey, S., Görgün, G. T., Roccaro, A. M., Anderson, K. C., & Ghobrial, I. M. (2015) · Immunological Reviews · doi:10.1111/imr.12233 · Cited by 391
Self-citationγ-secretase directly sheds the survival receptor BCMA from plasma cells
Laurent, S. A., Hoffmann, F. S., Kuhn, P.-H., Cheng, Q., Chu, Y., Schmidt-Supprian, M., Hauck, S. M., Schuh, E., Krumbholz, M., Rübsamen, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms8333 · Cited by 377
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI
Marsters, S. A., Yan, M., Pitti, R. M., Haas, P. E., Dixit, V. M., & Ashkenazi, A. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00566-2 · Cited by 374
Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Tai, Y.-T., Acharya, C., An, G., Moschetta, M., Zhong, M. Y., Feng, X., Cea, M., Cagnetta, A., Wen, K., van Eenennaam, H., et al. (2016) · Blood · doi:10.1182/blood-2016-01-691162 · Cited by 350
Self-citationMolecular pathogenesis of multiple myeloma and its premalignant precursor
Kuehl, W. M., & Bergsagel, P. L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61188 · Cited by 334
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404621 · Cited by 328
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
Zelle-Rieser, C., Thangavadivel, S., Biedermann, R., Brunner, A., Stoitzner, P., Willenbacher, E., Greil, R., & Jöhrer, K. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0345-3 · Cited by 319
Seckinger, A., Delgado, J. A., Moser, S., Moreno, L., Neuber, B., Grab, A., Lipp, S., Merino, J., Prosper, F., Emde, M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.002 · Cited by 312
Zheng, Y., Cai, Z., Wang, S., Zhang, X., Qian, J., Hong, S., Li, H., Wang, M., Yang, J., & Yi, Q. (2009) · Blood · doi:10.1182/blood-2009-05-220285 · Cited by 307
Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D., et al. (2002) · Blood · doi:10.1182/blood.v100.6.2195 · Cited by 294
Chauhan, D., Singh, A. V., Brahmandam, M., Carrasco, R., Bandi, M., Hideshima, T., Bianchi, G., Podar, K., Tai, Y.-T., Mitsiades, C., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.019 · Cited by 286
Self-citationSanchez, E., Li, M., Kitto, A., Li, J., Wang, C. S., Kirk, D. T., Yellin, O., Nichols, C. M., Dreyer, M. P., Ahles, C. P., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09241.x · Cited by 279
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs
Prota, A. E., Bargsten, K., Diaz, J. F., Marsh, M., Cuevas, C., Liniger, M., Neuhaus, C., Andreu, J. M., Altmann, K.-H., & Steinmetz, M. O. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408124111 · Cited by 279
Xu, S., & Lam, K.-P. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.4067-4074.2001 · Cited by 267
Feng, X., Zhang, L., Acharya, C., An, G., Wen, K., Qiu, L., Munshi, N. C., Tai, Y.-T., & Anderson, K. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3192 · Cited by 252
Self-citationHatzoglou, A., Roussel, J., Bourgeade, M.-F., Rogier, E., Madry, C., Inoue, J., Devergne, O., & Tsapis, A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1322 · Cited by 240
Tai, Y.-T., Li, X.-F., Breitkreutz, I., Song, W., Neri, P., Catley, L., Podar, K., Hideshima, T., Chauhan, D., Raje, N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0190 · Cited by 237
Self-citationTransforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells
Urashima, M., Ogata, A., Chauhan, D., Hatziyanni, M., Vidriales, M., Dedera, D., Schlossman, R., & Anderson, K. (1996) · Blood · doi:10.1182/blood.v87.5.1928.1928 · Cited by 235
Self-citationHipp, S., Tai, Y.-T., Blanset, D., Deegen, P., Wahl, J., Thomas, O., Rattel, B., Adam, P. J., Anderson, K. C., & Friedrich, M. (2017) · Leukemia · doi:10.1038/leu.2016.388 · Cited by 233
Self-citationChiu, A., Xu, W., He, B., Dillon, S. R., Gross, J. A., Sievers, E., Qiao, X., Santini, P., Hyjek, E., Lee, J.-W., et al. (2007) · Blood · doi:10.1182/blood-2006-04-015958 · Cited by 228
The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed
Laabi, Y., Gras, M.-P., Brouet, J.-C., Berger, R., Larsen, C.-J., & Tsapis, A. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.7.1147 · Cited by 211
Suen, H., Brown, R., Yang, S., Weatherburn, C., Ho, P. J., Woodland, N., Nassif, N., Barbaro, P., Bryant, C., Hart, D., et al. (2016) · Leukemia · doi:10.1038/leu.2016.84 · Cited by 198
Targeting B-Cell Maturation Antigen in Multiple Myeloma
Tai, Y.-T., & Anderson, K. C. (2015) · Immunotherapy · doi:10.2217/imt.15.77 · Cited by 188
Self-citationSerum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Ghermezi, M., Li, M., Vardanyan, S., Harutyunyan, N. M., Gottlieb, J., Berenson, A., Spektor, T. M., Andreu-Vieyra, C., Petraki, S., Sanchez, E., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.150896 · Cited by 188
Brischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S. A., Kiener, P., Kufer, P., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156750c · Cited by 187
A molecular compendium of genes expressed in multiple myeloma
Claudio, J. O., Masih-Khan, E., Tang, H., Gonçalves, J., Voralia, M., Li, Z. H., Nadeem, V., Cukerman, E., Francisco-Pabalan, O., Liew, C. C., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0008 · Cited by 185
Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber, H.-P., Sapra, P., Loganzo, F., & May, C. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.008 · Cited by 184
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
An, G., Acharya, C., Feng, X., Wen, K., Zhong, M., Zhang, L., Munshi, N. C., Qiu, L., Tai, Y.-T., & Anderson, K. C. (2016) · Blood · doi:10.1182/blood-2016-03-707547 · Cited by 184
Self-citationEndothelial cells in the bone marrow of patients with multiple myeloma
Vacca, A. (2003) · Blood · doi:10.1182/blood-2003-04-1338 · Cited by 180
Selectivity of BAFF/BLyS and APRIL for Binding to the TNF Family Receptors BAFFR/BR3 and BCMA
Day, E. S., Cachero, T. G., Qian, F., Sun, Y., Wen, D., Pelletier, M., Hsu, Y.-M., & Whitty, A. (2005) · Biochemistry · doi:10.1021/bi048227k · Cited by 176
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lee, L., Draper, B., Chaplin, N., Philip, B., Chin, M., Galas-Filipowicz, D., Onuoha, S., Thomas, S., Baldan, V., Bughda, R., et al. (2018) · Blood · doi:10.1182/blood-2017-05-781351 · Cited by 174
Sprynski, A. C., Hose, D., Caillot, L., Réme, T., Shaughnessy, J. D., Barlogie, B., Seckinger, A., Moreaux, J., Hundemer, M., Jourdan, M., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170464 · Cited by 173
Madry, C. (1998) · International Immunology · doi:10.1093/intimm/10.11.1693 · Cited by 168
Quintarelli, C., Vera, J., Savoldo, B., Giordano-Attianese, G., Pule, M., Foster, A., Heslop, H., Rooney, C., Brenner, M., & Dotti, G. (2007) · Blood · doi:10.1182/blood-2007-02-072843 · Cited by 164
Klein, J. S., Gnanapragasam, P. N. P., Galimidi, R. P., Foglesong, C. P., West, A. P., & Björkman, P. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811427106 · Cited by 163
Laâbi, Y., Gras, M.-P., Carbonnel, F., Brouet, J. C., Berger, R., Larsen, C., & Tsapis, A. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05482.x · Cited by 157
The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma
Derksen, P. W. B., de Gorter, D. J. J., Meijer, H. P., Bende, R. J., van Dijk, M., Lokhorst, H. M., Bloem, A. C., Spaargaren, M., & Pals, S. T. (2003) · Leukemia · doi:10.1038/sj.leu.2402875 · Cited by 156
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis
Gouill, S. L., Podar, K., Amiot, M., Hideshima, T., Chauhan, D., Ishitsuka, K., Kumar, S. K., Raje, N. S., Richardson, P. G. G., Harousseau, J., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1760 · Cited by 155
Self-citationBryant, C. E., Suen, H., Brown, R. D., Yang, S. S., Favaloro, J., Aklilu, E., Gibson, J., Ho, P. J., Iland, H. J., Fromm, P. D., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.34 · Cited by 139
Raja, K. R. M., Říhová, L., Zahradová, L., Klincová, M., Penka, M., & Hájek, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047077 · Cited by 131
Neri, P. E., Kumar, S. K., Fulciniti, M. T., Vallet, S., Chhetri, S., Mukherjee, S., Tai, Y., Chauhan, D., Tassone, P., Venuta, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0753 · Cited by 126
Self-citationYang, M., Hase, H., Legarda, D., Varughese, L., Seed, B., & Ting, A. T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.2814 · Cited by 123
Moreaux, J., Sprynski, A. C., Dillon, S. R., Mahtouk, K., Jourdan, M., Ythier, A., Moine, P., Robert, N., Jourdan, É., Rossi, J. F., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01262.x · Cited by 122
Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression
Kawano, Y., Zavidij, O., Park, J., Moschetta, M., Kokubun, K., Mouhieddine, T. H., Manier, S., Mishima, Y., Murakami, N., Bustoros, M. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci88169 · Cited by 120
Self-citationLeone, P., Berardi, S., Frassanito, M. A., Ria, R., Re, V. D., Cicco, S., Battaglia, S., Ditonno, P., Dammacco, F., Vacca, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-623975 · Cited by 117
Matthes, T., Dunand-Sauthier, I., Santiago‐Raber, M., Krause, K., Donzé, O., Passweg, J. R., McKee, T., & Huard, B. (2011) · Blood · doi:10.1182/blood-2011-01-332940 · Cited by 112
Hayashi, T., Hideshima, T., Nguyen, A. N., Munoz, O., Podar, K., Hamasaki, M., Ishitsuka, K., Yasui, H., Richardson, P., Chakravarty, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0632 · Cited by 110
Self-citationInterleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein
Urashima, M., Ogata, A., Chauhan, D., Vídriales, M., Teoh, G., Hoshi, Y., Schlossman, R., DeCaprio, J. A., & Anderson, K. C. (1996) · Blood · doi:10.1182/blood.v88.6.2219.bloodjournal8862219 · Cited by 107
Self-citationBellucci, R., Alyea, E. P., Chiaretti, S., Wu, C. J., Zorn, E., Weller, E. A., Wu, B., Canning, C. M., Schlossman, R. L., Munshi, N. C., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4463 · Cited by 101
Self-citationElsawa, S. F., Novak, A. J., Grote, D. M., Ziesmer, S. C., Witzig, T. E., Kyle, R. A., Dillon, S. R., Harder, B., Gross, J. A., & Ansell, S. M. (2005) · Blood · doi:10.1182/blood-2005-09-3552 · Cited by 94
An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies
Ramos, C. A., Asgari, Z., Liu, E., Yvon, E. S., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Stem Cells · doi:10.1002/stem.433 · Cited by 92
Design of chimeric antigen receptors with integrated controllable transient functions
Juillerat, A., Maréchal, A., Filhol, J.-M., Valton, J., Duclert, A., Poirot, L., & Duchateau, P. N. (2016) · Scientific Reports · doi:10.1038/srep18950 · Cited by 91
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Ryan, M. C., Hering, M. A., Peckham, D., McDonagh, C. F., Brown, L. L., Kim, K. M., Meyer, D. L., Zabinski, R. F., Grewal, I. S., & Carter, P. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0464 · Cited by 89
Braga, W. M. T., da Silva, B. R., de Carvalho, A. C., Maekawa, Y. H., Bortoluzzo, A. B., Rizzatti, E. G., Atanackovic, D., & Colleoni, G. W. B. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1589-9 · Cited by 88 · cited 1×
“In fact, immune-suppressive Treg markers Foxp3 and CTLA-4 are significantly upregulated in the BM aspirates of MM patients compared with normal donor controls (17), and increased Tregs are correlated with worse outcomes in MM (36, 38, 39).”
BackgroundBerdeja, J. G., Lin, Y., Raje, N. S., Munshi, N. C., Siegel, D. S. D., Liedtke, M., Jagannath, S., Maus, M. V., Turka, A., Lam, L. P., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.740.740 · Cited by 86
B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?
Hengeveld, P. J., & Kersten, M. J. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.3 · Cited by 85
Fan, F. (., Zhao, W., Liu, J., He, A., Chen, Y., Cao, X.-M., Yang, N., Wang, B., Zhang, P., Zhang, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.lba3001 · Cited by 83
Murray, B. C., Peterson, M. T., & Fecik, R. A. (2015) · Natural Product Reports · doi:10.1039/c4np00036f · Cited by 81
Fowler, J. A., Mundy, G. R., Lwin, S. T., & Edwards, C. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2067 · Cited by 78
Rudd, M. D., & Luse, D. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.35.21549 · Cited by 75
Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Lacey, S. F., Lancaster, E., Vogl, D. T., Dengel, K., Ambrose, D. E., Chen, F., Plesa, G., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1147.1147 · Cited by 74
The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma
Braga, W. M. T., Atanackovic, D., & Colleoni, G. W. B. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/293479 · Cited by 71
Current strategies for treatment of relapsed/refractory multiple myeloma
Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A. J., Lonial, S., & Richardson, P. G. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 71
Fan, F. (., Zhao, W., Liu, J., He, A., Chen, Y., Cao, X.-M., Yang, N., Wang, B., Zhang, P., Zhang, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.18_suppl.lba3001 · Cited by 66
The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies
Hoyos, V., & Borrello, I. (2016) · Blood · doi:10.1182/blood-2016-05-636357 · Cited by 62
Guadagnoli, M., Kimberley, F. C., Phan, U., Cameron, K., Vink, P. M., Rodermond, H. M., Eldering, E., Kater, A. P., van Eenennaam, H., & Medema, J. P. (2011) · Blood · doi:10.1182/blood-2011-01-330852 · Cited by 58
Berdeja, J. G., Lin, Y., Raje, N. S., Siegel, D. S. D., Munshi, N. C., Liedtke, M., Jagannath, S., Maus, M. V., Turka, A., Lam, L. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3010 · Cited by 57
Maia, S., Pelletier, M. R., Ding, J., Hsu, Y., Sallan, S. E., Rao, S. P., Nadler, L. M., & Cardoso, A. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020787 · Cited by 56
Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers
Bhakta, S., Raab, H. E., & Junutula, J. R. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_11 · Cited by 54
Joshua, D., Suen, H., Brown, R. D., Bryant, C. E., Ho, P. J., Hart, D. N. J., & Gibson, J. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.003 · Cited by 51
Sanchez, E., Smith, E. J., Yashar, M. A., Patil, S., Li, M., Porter, A. L., Tanenbaum, E. J., Schlossberg, R. E., Soof, C. M., Hekmati, T., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0538-x · Cited by 45
Yan, L., Shang, J., Kang, L., Shi, X., Zhou, J., Jin, S. L., Yao, W., Yao, Y., Chen, G., Zhu, Z., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.506.506 · Cited by 33
Cohen, A. D., Popat, R., Trudel, S., Richardson, P. G. G., Libby, E. N., Lendvai, N. K., Anderson, L. D., Sutherland, H. J., DeWall, S. L., Ellis, C. E., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1148.1148 · Cited by 29
Shen, X., Guo, Y., Qi, J., Shi, W., Wu, X., & Ju, S. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3169 · Cited by 25
B cell-activating factor: its clinical significance in multiple myeloma patients
Fragioudaki, M., Boula, A., Tsirakis, G., Psarakis, F., Spanoudakis, M., Papadakis, I., Pappa, C. A., & Alexandrakis, M. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1470-x · Cited by 24
Matthes, T., McKee, T., Dunand-Sauthier, I., Manfroi, B., Park, S., Passweg, J. R., & Huard, B. (2015) · Leukemia · doi:10.1038/leu.2015.68 · Cited by 23
Deng, S., Yuan, T., Cheng, X., et al. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0028-z · Cited by 21
Panowski, S. H., Kuo, T. C., Chen, A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.383.383 · Cited by 20
Moreno, L., Zabaleta, A., Alignani, D., Lasa, M., Maiso, P., Jelínek, T., Segura, V., Delgado, J. A., Rodríguez‐Otero, P., Prósper, F., et al. (2016) · Blood · doi:10.1182/blood.v128.22.2096.2096 · Cited by 10
Development of a New BCMAxCD3 Duobody® Antibody for Multiple Myeloma
Pillarisetti, K., Baldwin, E. T., Babich, A., Majewski, N., Barone, L. R., Li, Y., Zhang, X., Chin, D., Luistro, L. L., Mendonça, M., et al. (2016) · Blood · doi:10.1182/blood.v128.22.2116.2116 · Cited by 8
CAR-Ts move beyond B-cell cancers to myeloma
Dolgin, E. (2017) · Nature Biotechnology · doi:10.1038/nbt0717-599 · Cited by 7
Gantke, T., Reusch, U., Kellner, C., Klausz, K., Haneke, T., Knackmuss, S. H. J., Müller, T. R., Ellwanger, K., Fucek, I., Schniegler‐Mattox, U., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.3082.3082 · Cited by 7
Cited by
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
CAR T cell therapies for patients with multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0427-6 · Cited by 270
Treatment options for triple-class refractory multiple myeloma.
Mikhael, J. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.621 · Cited by 126
Chari, A., Touzeau, C., Schinke, C., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Morillo, D., Martinez-Chamorro, C., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00385-5 · Cited by 116
Metadata
- Authors
- Cho, S.-F., Anderson, K. C., & Tai, Y.-T.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-08-10
- Volume
- 9
- Pages
- 1821-1821
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2886837533
- Cited by
- 294
- References
- 126
- FWCI
- 20.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.